The Hyperuricemia drugs in development market research report provides comprehensive information on the therapeutics under development for Hyperuricemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Hyperuricemia. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Hyperuricemia and features dormant and discontinued products.
GlobalData tracks 39 drugs in development for Hyperuricemia by 37 companies/universities/institutes. The top development phase for Hyperuricemia is phase i with 15 drugs in that stage. The Hyperuricemia pipeline has 35 drugs in development by companies and four by universities/ institutes. Some of the companies in the Hyperuricemia pipeline products market are: Tonghua Dongbao Pharmaceutical, Nippon Chemiphar and Jiangsu Hengrui Medicine.
The key targets in the Hyperuricemia pipeline products market include Solute Carrier Family 22 Member 12, Xanthine Dehydrogenase/Oxidase, and Uric Acid.
The key mechanisms of action in the Hyperuricemia pipeline product include Solute Carrier Family 22 Member 12 Inhibitor with 14 drugs in Pre-Registration. The Hyperuricemia pipeline products include five routes of administration with the top ROA being Oral and six key molecule types in the Hyperuricemia pipeline products market including Small Molecule, and Recombinant Enzyme.
Hyperuricemia overview
High uric acid level, or hyperuricemia, is an excess of uric acid in blood. Symptoms include swollen, tender, and red joints; fever, chills, fatigue, and kidney problems (caused by formation of kidney stones), or problems with urination. Predisposing factors include age, family history, and certain medications. Treatment includes non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroid medications.
For a complete picture of Hyperuricemia’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
